HLB Life Science Co.,Ltd.(KR:067630)
â‚©2,650.00+365.00 (+15.97%)
KR:067630
HLB Life Science Co.,Ltd. financials statements
â‚©2,650.00
At close:+365.00 (+15.97%)
Want to see KR:067630 full AI Analyst Report?
HLB Life Science Co.,Ltd. (067630) Ratios
HLB Life Science Co.,Ltd. Ratios
KR:067630's free cash flow for Q4 2025 was ₩-12.61B. For the 2025 fiscal year, KR:067630's free cash flow was decreased by ₩-6.01B and operating cash flow was ₩-6.60B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.58 | 2.90 | 1.09 | 6.00 | 11.59 |
| Quick Ratio | 0.52 | 2.79 | 1.05 | 5.60 | 11.46 |
| Cash Ratio | 0.11 | 0.98 | 0.12 | 1.16 | 2.31 |
| Solvency Ratio | -0.52 | 0.09 | 0.01 | -0.28 | -1.94 |
| Operating Cash Flow Ratio | -0.19 | -0.60 | -0.07 | -1.11 | -1.04 |
| Short-Term Operating Cash Flow Coverage | -0.22 | -0.79 | -0.09 | -3.58 | 0.00 |
| Net Current Asset Value | â‚© -111.42B | â‚© 15.10B | â‚© -45.24B | â‚© -14.95B | â‚© 132.63B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.34 | 0.23 | 0.39 | 0.36 | 0.02 |
| Debt-to-Equity Ratio | 0.54 | 0.31 | 0.72 | 0.63 | 0.02 |
| Debt-to-Capital Ratio | 0.35 | 0.24 | 0.42 | 0.39 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.15 | 0.17 | 0.18 | 0.37 | 0.01 |
| Financial Leverage Ratio | 1.61 | 1.35 | 1.83 | 1.75 | 1.10 |
| Debt Service Coverage Ratio | -0.72 | 0.51 | 0.17 | -2.16 | -36.27 |
| Interest Coverage Ratio | -1.79 | -1.48 | -1.13 | -2.04 | -14.71 |
| Debt to Market Cap | 0.11 | 0.10 | 0.12 | 0.13 | 0.00 |
| Interest Debt Per Share | 1411.64 | 1297.47 | 1761.84 | 1472.76 | 55.01 |
| Net Debt to EBITDA | -1.76 | 2.75 | 6.56 | -2.55 | 0.53 |
| Profitability Margins | |||||
| Gross Profit Margin | -1.08% | -2.14% | -0.76% | -3.06% | -10.35% |
| EBIT Margin | -194.14% | 19.53% | 15.46% | -51.18% | -97.90% |
| EBITDA Margin | -182.67% | 25.30% | 23.31% | -45.93% | -93.25% |
| Operating Profit Margin | -45.95% | -24.27% | -25.04% | -20.24% | -34.55% |
| Pretax Profit Margin | -219.81% | 3.08% | -6.64% | -61.09% | -100.24% |
| Net Profit Margin | -218.12% | 6.00% | -6.11% | -54.58% | -92.14% |
| Continuous Operations Profit Margin | -218.35% | 6.07% | -6.03% | -54.58% | -92.14% |
| Net Income Per EBT | 99.23% | 194.90% | 92.01% | 89.35% | 91.92% |
| EBT Per EBIT | 478.39% | -12.69% | 26.51% | 301.76% | 290.17% |
| Return on Assets (ROA) | -20.87% | 1.14% | -1.41% | -13.20% | -18.20% |
| Return on Equity (ROE) | -33.56% | 1.54% | -2.59% | -23.16% | -20.02% |
| Return on Capital Employed (ROCE) | -5.85% | -5.11% | -8.52% | -5.24% | -7.18% |
| Return on Invested Capital (ROIC) | -4.51% | -4.71% | -5.54% | -4.56% | -6.59% |
| Return on Tangible Assets | -23.41% | 1.24% | -1.63% | -16.97% | -23.70% |
| Earnings Yield | -7.23% | 0.50% | -0.44% | -4.80% | -3.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.00 | 5.06 | 6.69 | 6.40 | 3.62 |
| Payables Turnover | 17.24 | 14.95 | 19.13 | 10.94 | 5.74 |
| Inventory Turnover | 6.81 | 17.11 | 18.75 | 9.44 | 33.37 |
| Fixed Asset Turnover | 0.35 | 1.26 | 1.34 | 1.08 | 2.42 |
| Asset Turnover | 0.10 | 0.19 | 0.23 | 0.24 | 0.20 |
| Working Capital Turnover Ratio | 1.76 | 1.80 | 1.35 | 0.72 | 0.35 |
| Cash Conversion Cycle | 214.99 | 68.99 | 54.95 | 62.30 | 48.09 |
| Days of Sales Outstanding | 182.56 | 72.07 | 54.56 | 57.03 | 100.70 |
| Days of Inventory Outstanding | 53.60 | 21.33 | 19.47 | 38.65 | 10.94 |
| Days of Payables Outstanding | 21.17 | 24.41 | 19.08 | 33.37 | 63.55 |
| Operating Cycle | 236.16 | 93.41 | 74.02 | 95.68 | 111.64 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -188.11 | -295.35 | -93.75 | -278.41 | -131.83 |
| Free Cash Flow Per Share | -400.90 | -548.80 | -295.20 | -387.49 | -156.26 |
| Dividend Paid and CapEx Coverage Ratio | -0.88 | -1.17 | -0.47 | -2.55 | -5.40 |
| Capital Expenditure Coverage Ratio | -0.88 | -1.17 | -0.47 | -2.55 | -5.40 |
| Operating Cash Flow Coverage Ratio | -0.14 | -0.26 | -0.06 | -0.20 | -3.05 |
| Operating Cash Flow to Sales Ratio | -0.50 | -0.31 | -0.10 | -0.30 | -0.26 |
| Free Cash Flow Yield | -3.54% | -4.85% | -2.30% | -3.66% | -1.26% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.83 | 199.86 | -229.44 | -20.83 | -26.98 |
| Price-to-Sales (P/S) Ratio | 30.16 | 12.00 | 14.01 | 11.37 | 24.86 |
| Price-to-Book (P/B) Ratio | 4.64 | 3.08 | 5.95 | 4.82 | 5.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -28.24 | -20.63 | -43.53 | -27.36 | -79.67 |
| Price-to-Operating Cash Flow Ratio | -60.18 | -38.33 | -137.07 | -38.07 | -94.44 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.98 | 2.56 | -1.46 | -0.41 |
| Enterprise Value Multiple | -18.27 | 50.17 | 66.66 | -27.30 | -26.13 |
| Enterprise Value | 1.53T | 1.30T | 1.52T | 1.25T | 1.30T |
| EV to EBITDA | -18.27 | 50.17 | 66.66 | -27.30 | -26.13 |
| EV to Sales | 33.38 | 12.69 | 15.54 | 12.54 | 24.37 |
| EV to Free Cash Flow | -31.25 | -21.82 | -48.28 | -30.17 | -78.08 |
| EV to Operating Cash Flow | -66.59 | -40.55 | -152.02 | -41.99 | -92.55 |
| Tangible Book Value Per Share | 2017.83 | 3267.13 | 1641.88 | 1353.81 | 1720.42 |
| Shareholders’ Equity Per Share | 2439.01 | 3675.88 | 2160.29 | 2197.06 | 2304.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | -0.97 | 0.09 | 0.11 | 0.08 |
| Revenue Per Share | 375.28 | 943.47 | 917.20 | 932.19 | 500.71 |
| Net Income Per Share | -818.56 | 56.64 | -56.01 | -508.81 | -461.38 |
| Tax Burden | 0.99 | 1.95 | 0.92 | 0.89 | 0.92 |
| Interest Burden | 1.13 | 0.16 | -0.43 | 1.19 | 1.02 |
| Research & Development to Revenue | 0.10 | 0.05 | 0.06 | 0.04 | 0.07 |
| SG&A to Revenue | 0.10 | 0.05 | 0.06 | 0.04 | 0.05 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.23 | -5.16 | 1.69 | 0.55 | 0.29 |
Currency in KRW

